Premium
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection
Author(s) -
Colvin Richard A,
Tanwandee Tawesak,
Piratvisuth Teerha,
Thongsawat Satawat,
Hui Aric Josun,
Zhang Hongfei,
Ren Hong,
Chen PeiJer,
Chuang WanLong,
Sobhonslidsuk Abhasnee,
Li Ruobing,
Qi Yin,
Praestgaard Jens,
Han Yi,
Xu Junfang,
Stein Daniel S
Publication year - 2015
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12671
Subject(s) - medicine , pegylated interferon , gastroenterology , adverse effect , hbeag , liver function , pharmacodynamics , pharmacokinetics , hepatitis b , hepatitis b virus , immunology , pharmacology , hepatitis c virus , hbsag , virus , ribavirin
Albinterferon is a fusion of albumin and interferon-α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon-α for the treatment of chronic hepatitis infections.